Vasiliki Rapti

National and Kapodistrian University of Athens — Greece

Medicine · Health Sciences

15h-index1.8kcitations54works3.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

COVID-19 Clinical Research Studies(28), Long-Term Effects of COVID-19(17), SARS-CoV-2 and COVID-19 Research(14), COVID-19 and healthcare impacts(6), Inflammatory Biomarkers in Disease Prognosis(4)

Publications49 total

Protection conferred by the Omicron XBB.1.5-adapted monovalent COVID-19 mRNA vaccine to patients hospitalized with COVID-19 in Greece in 2023–2024
Infectious Diseases Now·2025
Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Prognostic Markers of COVID-19 Disease Irrespective of Immunosuppression Status: A Case-Control Retrospective Single-Center Study
Pathogens·2025· 6 citedOpen Access
The Evolving Landscape of Infective Endocarditis: Difficult-to-Treat Resistance Bacteria and Novel Diagnostics at the Foreground
Journal of Clinical Medicine·2025· 6 citedOpen Access
Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial
Clinical Microbiology and Infection·2025· 2 citedOpen Access
Clarithromycin adjunct treatment leads to substantial financial savings in community-acquired pneumonia: sub-analysis of the ACCESS trial
Journal of Global Antimicrobial Resistance·2024Open Access
Prognostic cut-off values of neutrofil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for COVID-19: a case-control retrospective single-center study
Journal of Global Antimicrobial Resistance·2024Open Access
Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers of COVID-19 irrespective of patients immunosuppression status: a case-control retrospective single-center study
Journal of Global Antimicrobial Resistance·2024· 1 citedOpen Access
Protection conferred by booster vaccine doses in hospitalized patients with COVID-19 during the SARS-CoV-2 Omicron BA.2 and BA.5 epidemics from 2022 to 2023 in Greece
Infectious Medicine·2024· 2 citedOpen Access
Polyunsaturated fatty acid-derived lipid mediator networks characterize COVID-19 severity and risk for critical illness
2024· 1 citedOpen Access
Assessment of De-Escalation of Empirical Antimicrobial Therapy in Medical Wards with Recognized Prevalence of Multi-Drug-Resistant Pathogens: A Multicenter Prospective Cohort Study in Non-ICU Patients with Microbiologically Documented Infection
Antibiotics·2024· 3 citedOpen Access
The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDS
Respiratory Research·2024· 13 citedOpen Access
The Gordian Knot of C. auris: If You Cannot Cut It, Prevent It
Pathogens·2023· 14 citedOpen Access
Remdesivir: Effectiveness and Safety in Hospitalized Patients with COVID-19 (ReEs-COVID-19)—Analysis of Data from Daily Practice
Microorganisms·2023· 6 citedOpen Access
Remdesivir: Effectiveness and safety in hospitalized patients with COVID-19 (ReEs-COVID19) - Analysis of data from daily practice
Research Square (Research Square)·2023· 2 citedOpen Access
Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece
Vaccine·2023· 17 citedOpen Access
The Burden of COVID-19 in Adult Patients With Hematological Malignancies: A Single-center Experience After the Implementation of Mass-vaccination Programs Against SARS-CoV-2
In Vivo·2023· 2 citedOpen Access
Efficacy of Tocilizumab in Severely Ill COVID-19 Patients With Rapid Respiratory Deterioration: A Single Center Experience During the Third Pandemic Wave in Greece
In Vivo·2023Open Access
Prolonged<i>SARS</i>-CoV-2 Infection With Common Features in Two Patients Receiving Anti-CD20 Therapy
In Vivo·2023· 2 citedOpen Access
1153. Safety and Potential Efficacy of Exosomes Overexpressing CD24 (EXO-CD24) for the Prevention of Clinical Deterioration in Patients with Moderate or Severe COVID-19: A Phase II, Randomized, Single-blinded Study.
Open Forum Infectious Diseases·2022· 3 citedOpen Access
Delineating the SARS-CoV-2 Induced Interplay between the Host Immune System and the DNA Damage Response Network
Vaccines·2022· 10 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Garyphallia Poulakou(26), Konstantinos N. Syrigos(10), Vissaria Sakka(8), Konstantinos Leontis(8), Sotirios Tsiodras(7), Konstantinos Syrigos(7), Anastasia Antoniadou(6), Periklis Panagopoulos(6), Nikolaos Syrigos(6), G. Koumakis(6), Vasileios Petrakis(6), Paraskevi C. Fragkou(5), Dimitrios Basoulis(5), Ioannis P. Trontzas(5), Amalia Papanikolopoulou(5), Ioanna E. Galani(4), Αναστάσιος Κόλλιας(4), Eleni Kakalou(4), Maria Effrosyni Livanou(4), Garyfalia Poulakou(4)